Concord Biotech Limited receives final approval from USFDA for Teriflunomide Tablets

Concord Biotech Limited has been granted final approval from the United States Food and Drug Administration (USFDA) for marketing its Teriflunomide Tablets, 7 mg and 14 mg. Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis.

This approval reinforces our capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market. According to IQVIATM, the market size of Teriflunomide tablets is approximately $402 million in the US, and the global market size is approximately $908 million, indicating significant opportunities for expansion in the US and the global market.

Shares of Concord Biotech Limited was last trading in BSE at Rs. 1597.80 as compared to the previous close of Rs. 1579.75. The total number of shares traded during the day was 1116 in over 230 trades.

The stock hit an intraday high of Rs. 1622.95 and intraday low of 1589.70. The net turnover during the day was Rs. 1795970.00.

Source : Equity Bulls

Keywords

ConcordBiotech Pharmaceuticals INE338H01029 USFDA FinalApproval TeriflunomideTablets